Inhibition of Viability of Human Retinal Microvascular Endothelial Cells by Vialinin A Under High Glucose Condition

Overview

Journal Int J Ophthalmol

Specialty Ophthalmology

Date 2024 Oct 21

PMID 39430017

Authors

Zhi-Gang Chen

Gao-Qin Liu

Wei-Ming Liu

Pei-Rong Lu

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the effects of vialinin A on viability of human retinal endothelial cells (HRECs) under high glucose condition and its potential mechanism.

Methods: The HRECs were divided into four groups: normal glucose control group (NG, 5 mmol/L D-glucose), high glucose group (HG, 30 mmol/L D-glucose), HG+1 µmol/L vialinin A group, and HG+5 µmol/L vialinin A group. The cell viabilities were measured with cell counting kit-8 (CCK-8) assay for proliferation, with scratch assay for migration, and tube formation, for evaluation of the impact of vialinin A on cellular behaviour. Real-time PCR and Western blotting were used to determine the expression level of vascular endothelial growth factor (VEGF).

Results: The proliferative capacity and migration of HRECs was reduced by 5 µmol/L vialinin A in high glucose environment (both <0.05). Vialinin A also inhibited high-glucose-induced tube formation of HRECs. The expression level of VEGF and PI3K in HRECs was also significantly decreased by vialinin A (<0.05).

Conclusion: Vialinin A inhibits the cell viability of HRECs. It may serve as a potential target for anti-angiogenic therapy.

References

Raman R, Ganesan S, Pal S, Gella L, Kulothungan V, Sharma T . Incidence and Progression of Diabetic Retinopathy in Urban India: Sankara Nethralaya-Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SN-DREAMS II), Report 1. Ophthalmic Epidemiol. 2017; 24(5):294-302. DOI: 10.1080/09286586.2017.1290257. View

Kobialka P, Graupera M . Revisiting PI3-kinase signalling in angiogenesis. Vasc Biol. 2020; 1(1):H125-H134. PMC: 7439845. DOI: 10.1530/VB-19-0025. View

Dulull N, Kwa F, Osman N, Rai U, Shaikh B, Thrimawithana T . Recent advances in the management of diabetic retinopathy. Drug Discov Today. 2019; 24(8):1499-1509. DOI: 10.1016/j.drudis.2019.03.028. View

Tan T, Wong T . Diabetic retinopathy: Looking forward to 2030. Front Endocrinol (Lausanne). 2023; 13:1077669. PMC: 9868457. DOI: 10.3389/fendo.2022.1077669. View

Vasile F, Volpe S, Ambrosio F, Costa G, Unver M, Zucal C . Exploration of ligand binding modes towards the identification of compounds targeting HuR: a combined STD-NMR and Molecular Modelling approach. Sci Rep. 2018; 8(1):13780. PMC: 6137155. DOI: 10.1038/s41598-018-32084-z. View

Perais J, Agarwal R, Evans J, Loveman E, Colquitt J, Owens D . Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy. Cochrane Database Syst Rev. 2023; 2:CD013775. PMC: 9943918. DOI: 10.1002/14651858.CD013775.pub2. View

Teo Z, Tham Y, Yu M, Chee M, Rim T, Cheung N . Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. Ophthalmology. 2021; 128(11):1580-1591. DOI: 10.1016/j.ophtha.2021.04.027. View

Cui J, Gong R, Hu S, Cai L, Chen L . Gambogic acid ameliorates diabetes-induced proliferative retinopathy through inhibition of the HIF-1α/VEGF expression via targeting PI3K/AKT pathway. Life Sci. 2017; 192:293-303. DOI: 10.1016/j.lfs.2017.11.007. View

Zhang F, Li K, Yao X, Wang H, Li W, Wu J . A miR-567-PIK3AP1-PI3K/AKT-c-Myc feedback loop regulates tumour growth and chemoresistance in gastric cancer. EBioMedicine. 2019; 44:311-321. PMC: 6603849. DOI: 10.1016/j.ebiom.2019.05.003. View

10.

Chen Z, Liu G, Xiao Y, Lu P . Adrenomedullin22-52 suppresses high-glucose-induced migration, proliferation, and tube formation of human retinal endothelial cells. Mol Vis. 2014; 20:259-69. PMC: 3945807. View

11.

Hou X, Zhu F, Ni Y, Chen T, Du J, Liu X . USP4 is pathogenic in allergic airway inflammation by inhibiting regulatory T cell response. Life Sci. 2021; 281:119720. DOI: 10.1016/j.lfs.2021.119720. View

12.

Ahmad A, Nawaz M . Molecular mechanism of VEGF and its role in pathological angiogenesis. J Cell Biochem. 2022; 123(12):1938-1965. DOI: 10.1002/jcb.30344. View

13.

Sonowal H, Shukla K, Kota S, Saxena A, Ramana K . Vialinin A, an Edible Mushroom-Derived p-Terphenyl Antioxidant, Prevents VEGF-Induced Neovascularization In Vitro and In Vivo. Oxid Med Cell Longev. 2018; 2018:1052102. PMC: 5818888. DOI: 10.1155/2018/1052102. View

14.

Papadopoulou-Marketou N, Chrousos G, Kanaka-Gantenbein C . Diabetic nephropathy in type 1 diabetes: a review of early natural history, pathogenesis, and diagnosis. Diabetes Metab Res Rev. 2016; 33(2). DOI: 10.1002/dmrr.2841. View

15.

Ved N, Hulse R, Bestall S, Donaldson L, Bainbridge J, Bates D . Vascular endothelial growth factor-Ab ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina. Clin Sci (Lond). 2017; 131(12):1225-1243. PMC: 5450016. DOI: 10.1042/CS20170102. View

16.

Tang L, Xu G, Zhang J . Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy. Neural Regen Res. 2022; 18(5):976-982. PMC: 9827774. DOI: 10.4103/1673-5374.355743. View

17.

Yang L, Yu S, Yang Y, Zhao Y, Wang F, Chen Y . Muscone derivative ZM-32 inhibits breast tumor angiogenesis by suppressing HuR-mediated VEGF and MMP9 expression. Biomed Pharmacother. 2021; 136:111265. DOI: 10.1016/j.biopha.2021.111265. View

18.

Yoshioka Y, Namiki D, Makiuchi M, Sugaya K, Onose J, Ashida H . Vialinin A and thelephantin G, potent inhibitors of tumor necrosis factor-α production, inhibit sentrin/SUMO-specific protease 1 enzymatic activity. Bioorg Med Chem Lett. 2016; 26(17):4237-40. DOI: 10.1016/j.bmcl.2016.07.051. View

19.

Yang J, Liu Z . Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy. Front Endocrinol (Lausanne). 2022; 13:816400. PMC: 9174994. DOI: 10.3389/fendo.2022.816400. View

20.

Mao M, Xia Q, Zhan G, Bing H, Zhang C, Wang J . Vialinin A alleviates oxidative stress and neuronal injuries after ischaemic stroke by accelerating Keap1 degradation through inhibiting USP4-mediated deubiquitination. Phytomedicine. 2024; 124:155304. DOI: 10.1016/j.phymed.2023.155304. View